The Manila Times

Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Mi…

Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in ...
Business Wire

OPM Reports Final Results of Its Phase 1 Study With RIPK2 Inhibitor OPM-101, With Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1b/2a

DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the ...
Seeking Alpha

Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data

Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...
Nasdaq

Monte Rosa Therapeutics Begins Phase 1 Study of MRT-8102 for Inflammatory Conditions with Initial Results Expected in H1 2026

Monte Rosa Therapeutics, Inc. has initiated a Phase 1 study for MRT-8102, a novel molecular glue degrader targeting the NEK7 protein to treat inflammatory conditions linked to the NLRP3 inflammasome.
TipRanks on MSN

Actuate announces results from phase 1 portion of study of elraglusib

Actuate Therapeutics (ACTU) announced results from the phase 1 portion of its phase 1/2 clinical study evaluating elraglusib as a monotherapy or ...